Steppogenin (2 mg/kg, IP, once) inhibits tumor growth and angiogenesis[1].
Steppogenin (2 mg/kg, IP, once) shows the highest distribution to the liver and spleen (25.5-fold and 9.74-fold AUC ratio, respectively) with significantly higher T1/2[1].
Pharmacokinetic Parameters of Steppogenin in male C57BL/6 J mice[1].
| Cmax (ng/mL) | Tmax (h) | T1/2 (h) | AUC8h (ng/mLh) | AUC∞ (ng/mLh) | AUC ratio |
| Plasma | 448 ± 113 | 0.25 | 0.49 ± 0.14 | 283 ± 98.9 | 284 ± 97.8 | 1 |
| Tumor | 635 ± 114 | 0.3 ± 0.1 | 1.87 ± 0.87 | 1078 ± 494 | 1252 ± 547 | 4.58 |
| Liver | 4319 ± 1063 | 0.25 | 1.72 ± 0.26 | 6733 ± 1300 | 6967 ± 1200 | 25.5 |
| Lung | 521 ± 181 | 0.25 | 0.36 ± 0.12 | 261 ± 96.1 | 280 ± 106 | 1.02 |
| Heart | 285 ± 15.2 | 0.25 | 0.2 | 107 ± 44.3 | 176.9 | 0.65 |
| Kidney | 1225 ± 463 | 0.25 | 0.33 ± 0.01 | 628 ± 234 | 624.7 ± 238 | 2.35 |
| Spleen | 6110 ± 2954 | 0.25 | 0.47 ± 0.01 | 2443 ± 1155 | 2663 ± 1289 | 9.74 |
| Brain | 309 ± 95.7 | 0.25 | 1.36 ± 0.46 | 191 ± 67 | 241 ± 75.4 | 0.88 |
| Animal Model: | C57BL/6 J mice (6-week-old, male, Lewis lung carcinoma (LLC) allograft tumor model)[1] |
| Dosage: | 2 mg/kg |
| Administration: | IP, once |
| Result: | Significantly suppressed tumor growth. |
| Animal Model: | C57BL/6 J mice (6-week-old, male, Lewis lung carcinoma (LLC) allograft tumor model)[1] |
| Dosage: | 2 mg/kg |
| Administration: | IP, once (Pharmacokinetic Analysis) |
| Result: | Showed the highest distribution to the liver and spleen (25.5-fold and 9.74-fold AUC ratio, respectively) with significantly higher T1/2. may not be accumulated even in the highly distributed tissues after the repeated administration of steppogenin. |
